explore -WSS

explore

author：knowledge 2025-08-11 07:59:09 - browse：96138

he exterior of the U.S. Capitol building is seen at sunrise — Sarah Silbiger/Getty Images

WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： FDA panel to weigh approval of NurOwn, controversial ALS drug

knowledge

WSS

Change Healthcare cyberattack shows risk of industry consolidation

Readout LOUD podcast: possible new ALS drug, artificial wombs

Neuroscience renaissance leads to new crop of psychiatric drugs

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Medicare isn't yet testing food as medicine

Elisabeth Bik tackles the widespread issue of research misconduct

leisure time

explore

entertainment

Alkermes shareholders re

Intarcia’s device

Dobbs anniversary: the lost opportunity of abortion as health care

Microbiome research is starting to find links to chronic diseases

Moonlake's readout produced a cash windfall. Risks remain

Medicare Advantage isn’t working — for anyone

Bright Health sells Medicare Advantage business to Molina

Medical student insurance fails on mental health care coverage

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hearing on Medicare drug price negotiation gets unusually heated

focus

Neuroscience renaissance leads to new crop of psychiatric drugs

Biotech stock slump in 2023: awaiting the turnaround

Neuroscience renaissance leads to new crop of psychiatric drugs

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Biotech stock slump in 2023: awaiting the turnaround

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

focus

knowledge

Wikipedia

Wikipedia